Tumor-Associated Macrophages: From Basic Research to Clinical Application
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (1 May 2021) | Viewed by 3433
Special Issue Editor
Interests: macrophages differentiation; macrophage metabolism and epigenetics; molecular mechanisms of chronic inflammation in cancer, diabetes, vascular complications, and tissue regeneration; macrophage biomarkers; biomaterials for macrophage drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumor-associated macrophages (TAMs) are major innate immune cells in a tumor microenvironment and can constitute up to 50% of the mass of human tumors. TAMs are highly heterogeneous cells that originate from resident tissue-specific macrophages and from newly recruited monocytes. TAM variability strongly depends on cancer type, stage, and intratumoral heterogeneity. The majority of TAMs are programmed by TME to support primary tumor growth and metastatic spread. However, in some types of cancer, TAM can also restrict tumor growth and metastasis. TAM can also cooperate or interfere with anticancer therapy. There are three major mechanistic levels that define macrophages phenotype and functional polarization: transcriptional factors, epigenetic modifications, and metabolic pathways, and understanding the complexity of the interaction between thee pathways is the next challenge that will allow identifying pharmacological targets for immunomodulatory therapy in specific tumor types. The development of delivery systems for specific targeting for pro-tumoral TAMs in different types of cancer is the next task for biotechnology.
In the Special Issue, we invite submissions that describe fundamental aspects of TAM biology, interaction of TAM with cancer cells, and other cells in tumor microenvironment; novel preclinical models to decipher the function of TAM; association of TAM with various human cancers; new TAM biomarkers for the prediction of metastasis and therapy responses; therapeutic targets in TAM, and immunomodulatory therapeutic approaches based on targeting of TAM.
Prof. Dr. Julia Kzhyshkowska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor-associated macrophage
- cytokine
- transcriptional program
- signal transduction
- epigenetics
- phagocytosis
- biomarker
- cancer
- metastasis
- immunotherapy
